Regeneron posted total revenues of $440 million for the three months ending March 31, and non-GAAP net income of $201 million, or $1.78 per share, soundly beating estimates of 95 cent per share...reported total revenues of $2.53 billion and non-GAAP net income $801.9 million, or 48 cents per share, falling short of analyst estimates of $2.58 billion in revenue and earnings per share of 50 cents

Incyte's total revenues for the three-month period were $71.1 million, besting consensus estimates of $68.2 million

reported total revenues of $1.4 billion in the first quarter of 2013, a 10 percent increase compared to the first quarter of 2012...Total revenue was $1.465 billion, compared to $1.273 million in the first quarter of 2012

Since it was approved in 1997, Lipitor has generated more than $130 billion in sales for Pfizer and comprised 20 percent of the company's total revenue, according to a Congressional Research Service (CRS) report on the impact of the pharmaceutical patent cliff. (See BioWorld Today, April 10, 2012.) However, the pharma appears to have shrugged off this dramatic loss in revenue as reflected by an almost 28 percent increase in its share price since BIO 2012

Total revenue for the three-month period was $229.9 million, falling short of analyst estimates of $243 million

United Therapeutics Corp., of Silver Spring, Md., reported total revenues of $243.8 million for the fourth quarter, with net income totaling $83.3 million, or $1.65 per share

The company reported total revenue of €21.6 million for the period and (non-GAAP-adjusted) earnings before interest, depreciation and taxes (EBIDTA) of €3 million

The company reported total revenue of €21.6 million for the period and (non-GAAP-adjusted) earnings before interest, depreciation and taxes (EBIDTA) of €3 million

Revenue for the full year and fourth quarter of 2012, was $362.2 million and $127.9 million, respectively, as compared to total revenue of $447.2 million and $237.0 million for the comparable periods in 2011

The company's total revenues for the quarter were $113.8 million, compared to $28.9 million for the same period in 2011...Ligand Pharmaceuticals Inc., of San Diego, had total revenues of $13.6 million for 4Q 2012, compared to $12.9 million for 4Q 2011

Total revenues in the fourth quarter were $63.9 million, compared to $48.9 million in the fourth quarter of 2011...Total revenues for the year were $210.8 million, compared to $94.8 million in 2011

Gilead's total revenues for the fourth quarter of 2012 increased 18 percent over the same period in 2011, to $2.59 billion, and net income was $762.5 million, or 47 cents per diluted share

Total revenues for the three months ending Dec. 31 totaled $1.4 billion – consensus estimates had predicted $1.39 billion – while non-GAAP earnings per share (EPS) came in at $1.40, slightly below estimates of $1.46, a miss attributed in part to a $29 million tax correction for the quarter

For the full year, total revenues increased 11 percent to about $17.2 million, with 9 percent product sales growth driven by strong performance across the portfolio...Full year total revenues for 2012 were about $5.5 million and net product sales were about $5.3 million

Total revenues are expected to reach as high as $325 million, with net income of $50 million to $54 million, for adjusted earnings before interest, taxes, depreciation, and amortization of between $73 million and $79 million

Anticoagulant Angiomax (bivalirudin) brought in sales of $123.8 million in the third quarter of 2012, comprising about a third of the firm's total revenue for the three-month period

Overall, AbbVie fell in the middle of the pack when combining pipeline, inline product growth and patent exposure scores and adjusting by total revenue

The company has taken advantage of its royalty streams from partnered programs, which brought in total revenues of $27 million in the third quarter

Canada, France, Germany, Japan, the UK and the U.S., combined, still generate nearly 60 percent of the industry's total revenues